Xoma Technology Ltd.

Robert Bauer

Patrick J Scannon

Alan M Solinger

Mark Leslie White

Marina Roell

Daniel H Bedinger

John Corbin

The present invention provides polypeptide binding agents, e.g. antibodies, that exhibit the ability to kinetically modulate the binding and signaling of biological signaling complexes, e.g., receptor-ligand complexes; methods of identifying such polypeptide binding agents, methods of making such polypeptide binding agents, compositions comprising such polypeptide binding agents, and methods of using such polypeptide binding agents.

Screening methods

Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1&#x3b2; antibody or fragment thereof.

Methods for the treatment of IL-1&#x3b2; related diseases

Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, decreased insulin production, hyperglycemia, hypoinsulinemia, metabolic syndrome, Type 1 diabetes and obesity, comprising administering to a subject an effective amount of anti-IL-1&#x3b2; antibody or fragment thereof.

Methods for treating IL-1&#x3b2; related diseases by administering an anti-IL-1&#x3b2; antibody

Disclosed are methods for improvement of beta cell function in a subject using an anti-IL-1&#x3b2; antibody or fragment thereof.

Growing community of inventors

Pleasant Hill, CA, United States of America

Robert Bauer